Alivus Life Sciences Releases Q4 FY26 Earnings Call Transcript
Alivus Life Sciences reported Q4 FY26 revenue of ₹689 crore and full-year revenue of ₹2,552 crore, up 6.1% and 6.9% YoY respectively. EBITDA margins reached 33.6% for the full year, driven by non-GPL segment growth and operational efficiencies. The company plans ₹540 crore capex in FY27, funded internally, and expects to maintain EBITDA margins of 30-32%.
The announcement is the release of an earnings call transcript, which provides detailed insights into the company's financial performance and strategic outlook. While it confirms positive results and future plans, it does not introduce new material events. The information is crucial for investors seeking detailed understanding but is a follow-up to the initial results announcement.
The company reported strong financial performance with revenue growth and improved EBITDA margins. Management expressed confidence in future growth and margin sustainability, highlighting strategic progress and robust pipeline. The transcript release itself is a routine update following the earnings call.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced the availability of the transcript for its Earnings Call held on May 15, 2026. This call discussed the financial results for the fourth quarter and the full year ended March 31, 2026.
During the call, management highlighted significant progress over the past two years under Nirma's promotership, emphasizing enhanced financial strength and a strengthened business foundation for sustainable growth. The company has focused on building a more diversified and resilient business model, expanding its product portfolio, and improving overall business quality. This is reflected in the increasing contribution of the non-GPL segment, which grew from 59% in FY22 to 71% in FY26, reducing dependence on the GPL business. The CDMO business also saw a meaningful recovery starting in Q3 FY26.
Financially, for the full year FY26, Alivus reported revenues of ₹2,552 crore, a 6.9% year-on-year growth, with the non-GPL business leading at 13% growth. EBITDA margins stood at 33.6%, an expansion of 360 basis points year-on-year, reaching a historic high. This improvement was achieved through a favorable product mix, disciplined cost management, operational efficiencies, and a focus on high-value differentiated products, while maintaining a net debt-free position.
For Q4 FY26, revenue from operations was ₹689 crore (up 6.1% YoY), with EBITDA at ₹237 crore (up 13.8% YoY) and EBITDA margins at 34.4% (up 230 bps YoY). PAT for the quarter was ₹163 crore.
Capex plans include Solapur Phase 1 becoming operational in Q2 FY27 and the construction of a new R&D center in Taloja underway. The company has a robust pipeline with over 611 DMF and CEP filings globally. Looking ahead, Alivus expects to sustain EBITDA margins in the range of 30% to 32% and plans to incur a capex of approximately ₹540 crore in FY27, funded through internal accruals.
Management also addressed questions regarding a fire incident at the Dahej plant, stating a ₹20 crore loss was booked and no significant spillover is expected. Forex gains of ₹31 crore were recorded for the full year. The company expects continued growth in its non-GPL business, aiming for double-digit revenue growth, and is exploring inorganic opportunities to enhance its existing platform. The backward integration at Solapur is expected to be implemented once it becomes operational in Q2 FY27, potentially benefiting margins. High potency API (HPAPI) development is ongoing, with initial revenue expected from exhibit batch quantities until patent expiries in 2028. Price erosion in the base business (excluding GPL and CDMO) was noted at approximately 5.5%. The company is focused on maintaining a high-quality business with good margin profiles and cash generation, rather than aggressive growth at the expense of margins.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.